Technical Data
VEGF Receptor 2 (CD309 antigen, Fetal liver kinase 1, FLK1, KDR, Kinase insert domain receptor, KRD1, Ly73, Protein tyrosine kinase receptor FLK1, Vascular endothelial growth factor receptor 2, VEGFR, VEGFR2)
Vascular endothelial growth factor receptor 2 (VEGFR-2, KDR, Flk-1) is a major receptor transducing the effects of VEGF into endothelial cells. Upon ligand binding, VEGFR-2 undergoes autophosphorylation and becomes activated (1). Major autophosphorylation
sites of VEGFR-2 are located in the kinase insert domain (Tyr951/996) and in the tyrosine kinase catalytic domain (Tyr1054/1059) (2). Activation of the receptor leads to rapid recruitment of the adaptor proteins, including Shc, GRB2, PI3 kinase, Nck and the protein
tyrosine phosphatases SHP-1 and SHP-2 (3). The signaling of VEGFR-2 is necessary for the execution of VEGF-stimulated proliferation, chemotaxis and prouting, as well as survival of cultured endothelial cells in vitro and angiogenesis in vivo (4).

Suitable for use in Western Blotting. Other applications not tested.

Recommended Dilution:
Western Blot: 1:1000

Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and add glycerol (30-50%). Freeze at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer
PabIgGAffinity Purified
100ul-20CBlue IceHumanRabbit
Not determined
Synthetic peptide (KLH coupled) corresponding to residues near the carboxy- terminal sequence of human VEGF receptor 2
Protein A and peptide affinity chromatography
Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 100ug/ml BSA, 50% glycerol
Detects overexpressed levels of VEGF receptors. It does not crossreact with other members of VEGF receptor family
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
(1) Meyer, M. et al. (1999) EMBO J. 18, 363374. (2) Dougher-Vermazen, M. et al. (1994) Biochem. Biophys. Res. Commun. 205, 728738. (3) Kroll, J. and Waltenberger, J. (1997) J. Biol. Chem. 272, 3252132527. (4) Karkkainen, M.J. and Petrova, T. (2000) Oncogene 19, 55985605. (5) Rahimi, N. et al. (2000) J. Biol. Chem. 275, 1698616992.